Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis.

Genetic factors, in particular human leukocyte antigens (HLAs) are important determinants of susceptibility to sarcoidosis, a chronic granulomatous disease of undetermined etiology. To clarify the role of HLA in sarcoidosis we determined HLA-DR and -DQ alleles in case-control samples from three European populations (United Kingdom, Czech, and Polish) and compared these results with those published for three additional populations (Italian, Japanese, and Scandinavian) to determine whether the HLA-DR and/or -DQ alleles act as ethnic-dependent, or ethnic-independent modifiers of disease risk. Although variations were apparent in the alleles associated with susceptibility, reductions in the frequency of alleles associated with protection were remarkably consistent in the six populations. Previously detected associations between single-nucleotide polymorphisms at the TAP2 locus and sarcoidosis were shown to be due to linkage disequilibrium with the HLA-DR locus. The protective HLA-DR alleles, which encode the DR1 and DR4 antigens, were found to share characteristic small hydrophobic residues at position 11, which were replaced by small hydrophilic residues in the remaining, nonprotective, HLA-DR alleles. This residue position is within a pocket of the HLA-DR complex antigen binding groove (designated P6), where it is the only variable amino acid and therefore determines the peptide binding preferences of this pocket. A highly significant reduction in the frequency of individuals carrying HLA-DR alleles with a hydrophobic residue at position 11 was observed in the sarcoidosis cases in the three populations we examined. This suggests this HLA-DR residue is an important protective marker in sarcoidosis.

[1]  G. Hunninghake,et al.  ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. , 1999, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[2]  J. Gerdes,et al.  TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. , 1999, European cytokine network.

[3]  Y. Ina,et al.  HLA and sarcoidosis in the Japanese. , 1989, Chest.

[4]  R. Lechler,et al.  Disease susceptibility, transplantation and the MHC. , 1995, Immunology today.

[5]  M. Barnardo,et al.  Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). , 1995, Tissue antigens.

[6]  J. Muller-Quernheim Sarcoidosis: immunopathogenetic concepts and their clinical application , 1998 .

[7]  N. Mehra,et al.  HLA and sarcoidosis. , 1988, Sarcoidosis.

[8]  J. Grunewald,et al.  HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. , 1997, American journal of respiratory and critical care medicine.

[9]  M. Iannuzzi,et al.  Analysis of HLA-DPB1 polymorphisms in African-Americans with sarcoidosis. , 1998, American journal of respiratory and critical care medicine.

[10]  Y. Ina,et al.  Antigen-presenting capacity in patients with sarcoidosis. , 1990, Chest.

[11]  Marie-Paule Lefranc,et al.  IMGT, the international ImMunoGeneTics database , 2001, Nucleic Acids Res..

[12]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[13]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[14]  R. D. du Bois,et al.  The density of HLA-DR antigen expression on alveolar macrophages is increased in pulmonary sarcoidosis. , 1986, Clinical and experimental immunology.

[15]  K. Welsh,et al.  Comprehensive HLA-DP typing using polymerase chain reaction with sequence-specific primers and 95 sequence-specific primer mixes. , 1998, Tissue antigens.

[16]  K. Welsh,et al.  Analysis of MHC encoded antigen-processing genes TAP1 and TAP2 polymorphisms in sarcoidosis. , 1999, American journal of respiratory and critical care medicine.

[17]  M. Martinetti,et al.  "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries. , 1995, American journal of respiratory and critical care medicine.

[18]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.